CODX 8-K SEC Filing Analysis

Latest settled — T+20d

CODX ▼ -5.56% at T+20d

SHORT call ✓ call won +5.56% · α vs SPY +15.28% · entry $1.62 → $1.53

Next anchor: T+60d in 5w

Currently $3.83 · -136.41% from $1.62 entry (call sign-flipped)

Entry anchored
Mar 31, 04:02 PM ET
via Databento tick

T+1d

-4.94%

call +4.94% · α +5.02%

$1.54

settled 7w ago

T+5d

-11.11%

call +11.11% · α +14.88%

$1.44

settled 6w ago

T+20d

-5.56%

call +5.56% · α +15.28%

$1.53

settled 22d ago

T+60d

—

call — · α —

—

in 5w

Price Chart

Loading chart...

Executive Summary

Co-Diagnostics reported a significant year-over-year revenue decline from $3.9M to $0.6M in 2025, driven by lower grant revenue, while net loss widened to $46.9M due to an $18.9M non-cash impairment charge. Despite progress in joint ventures and regulatory milestones, the deteriorating financial performance dominates the narrative.

Key Financial Metrics

Gross Margin

64.27%

Actionable Insight

Monitor upcoming quarters for signs of revenue stabilization and commercialization progress in India; the significant impairment and cash burn raise sustainability concerns despite strategic advancements.

Key Facts

Revenue dropped 84.7% YoY to $622,489 in 2025 from $3.92M in 2024, primarily due to lower grant revenue
Net loss increased to $46.9M ($35.25/share) from $37.6M ($37.22/share) in 2024, driven by $18.9M impairment charge
Cash, cash equivalents, and marketable securities fell to $11.9M from $29.7M in 2024
Company raised $10.8M through two equity offerings in 2025, indicating dilutive capital raising
Received CDSCO license for PCR Pro® instrument in India and expanded CoSara's territory across South Asia

Financial Impact

Revenue down 84.7% YoY, net loss up 24.7%, with $18.9M impairment charge and $18M cash burn

revenuenet losscash flowdilutionimpairment

Risk Factors

Continued reliance on dilutive equity financing to fund operations
Failure to commercialize joint ventures (CoSara, CoMira) could further pressure financials
Risk of Nasdaq delisting if bid price falls below $1.00 for 30 consecutive days during monitoring period

Market Snapshot

Exchange

Nasdaq

Sector

Surgical & Medical Instruments & Apparatus

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001493152-26-014129
Document: form8-k.htm	0001493152-26-014129
Document: 0001493152-26-014129-index-headers.html	0001493152-26-014129
Document: 0001493152-26-014129-index.html	0001493152-26-014129
Document: 0001493152-26-014129.txt	0001493152-26-014129
8-K Data (Synthetic)	0001493152-26-014129

5 reports for CODX

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for CODX — sortable, filterable
	Type				Now
May 21, 2026 today	8-K BEARISH ★ 8/10	$2.86 awaiting T+5	awaiting T+5	—	$3.83 (−33.75%)
May 18, 2026 3d ago	EFFECT BEARISH ★ 8/10	—	awaiting T+5	—	—
May 14, 2026 6d ago	8-K BEARISH ★ 7/10	$1.64 awaiting T+5	awaiting T+5	—	$3.83 (−133.53%)
May 12, 2026 8d ago	S-3 BEARISH ★ 8/10	$1.60 $1.97	▼ −23.13%	▼ −24.28%	$3.83 (−139.37%)
Mar 31, 2026 7w ago	8-K BEARISH ★ 7/10	$1.62 $1.44	▲ +11.11%	▲ +14.88%	$3.83 (−136.41%)

US Market Status

Market Open — Closes in 3h 57m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access